Abstract 18905: Novel Oral Anticoagulant Availability Increases Appropriate Use of Anticoagulants for Nonvalvular Atrial Fibrillation in the Elderly Aged >= 75 Years Old in Clinical Practice

IntroductionRegistry data indicate that anticoagulation (AC) is underprescribed in patients (pts) with nonvalvular atrial fibrillation (NVAF), especially in the elderly. Novel oral anticoagulants (NOAC) offer several advantages compared with warfarin, including predictable pharmacokinetics, minimal...

Full description

Saved in:
Bibliographic Details
Published in:Circulation (New York, N.Y.) N.Y.), 2016-11, Vol.134 (Suppl_1 Suppl 1), p.A18905-A18905
Main Authors: Zheng, Qi, Aneke-Nash, Chino, Halperin, Jonathan L, Vorchheimer, David A
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:IntroductionRegistry data indicate that anticoagulation (AC) is underprescribed in patients (pts) with nonvalvular atrial fibrillation (NVAF), especially in the elderly. Novel oral anticoagulants (NOAC) offer several advantages compared with warfarin, including predictable pharmacokinetics, minimal food drug interactions and no INR monitoring. We examined the impact of NOAC availability on the appropriate use of oral AC for stroke prevention in elderly pts with NVAF.MethodsRecords of all pts aged ≥ 18 yrs old with NVAF within the Montefiore Medical Center between 1/1/07-12/31/14 were reviewed. The proportion of pts receiving any AC [warfarin, dabigatran, rivaroxaban or apixaban] was compared during the 4-year interval before (2007-2011, pre-) and after (2011-2014, post-) NOAC release in Oct 2010.Results16526 pts with NVAF and CHADS2 score ≥ 1 were divided according to age (
ISSN:0009-7322
1524-4539